Exicure, акция обыкновенная (US30205M3097, XCUR, 2H0, XCUR.P)

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary spherical nucleic acid (SNA) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, IL.

• Выручка
• Чистая прибыль
• EBITDA
• Активы
• Капитал
• Рентабельность по EBITDA (%)
• Чистый долг / EBITDA
• Общий долг / Капитал